Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 10
283
Views
6
CrossRef citations to date
0
Altmetric
Short Communications

Bioactive constituents from seeds of Annona Senegalensis Persoon (Annonaceae)

, , , , &
Pages 1746-1751 | Received 03 Apr 2019, Accepted 16 Jun 2019, Published online: 28 Jun 2019
 

Abstract

Column chromatography led to the isolation and full characterization of N-cerotoyltryptamine (1) previously described in a mixture of 5 compounds, asimicin (2) and ent-19-Carbomethoxykauran-17-oic acid (3) isolated from this species for first time alongside stigmasterol glycoside (4) and lacceroic acid (5). The structures of the compounds were established by extensive EIMS, HRESIMS, 1 D and 2 D NMR studies. Compound 1 and the extract AS were more potent inhibitors of ROS with IC50 values of 2.7 ± 0.1 µg/mL and 8.7 ± 10.2 µg/mL respectively than Ibuprofen (11.2 ± 1.9 µg/mL) as a standard anti-inflammatory drug. Compound 2 showed high inhibition on nitric oxide (IC50 = 3.9 ± 0.2 µg/mL), almost 6 times more active than the standard compound L-NMMA (IC50 = 24.2 ± 0.8 µg/mL) used. Compounds showed relatively low toxicity on NIH-3T3 fibroblast cells compared to standard. The results indicate that compounds 1 and 2 are potent anti-inflammatory drug candidates.

GRAPHICAL ABSTRACT

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by TWAS PG Fellowship (FR number: 3240293193) and the HEC Project (Number: 5738).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.